Navigation Links
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Date:12/4/2007

LEUVEN, Belgium, December 4 /PRNewswire/ --

- Microplasmin Shows Clear Promise in Back of the Eye Disease, With Treated Patients Achieving Macular Hole Closure and Traction Release Without Need for Vitrectomy

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular and eye diseases, will today present results from its Phase IIa MIVI IIT trial at the American Society of Retina Specialists (ASRS) 25th Annual Meeting in Indian Wells, California. The trial, which delivered positive clinical results in a number of the treated patients, was designed to evaluate both the safety and efficacy of microplasmin injection for the treatment of vitreomacular traction, an important cause of back of the eye disease. The results of the study will be presented by Professor Peter Stalmans, University Hospitals, Leuven, Belgium.

Vitreomacular traction is a condition where the vitreous (the central fluid part of the eye) has an abnormally strong adhesion to the surface of the macula (the part of the retina responsible for detailed vision). Due to this, the macula may become distorted creating poor or deficient vision. Vitreomacular traction can also lead to sight threatening conditions such as macular holes or macular edema.

In current practice, these conditions are treated by a highly skilled surgical procedure called vitrectomy. The procedure uses suction to remove the vitreous from the eye to induce posterior vitreous detachment or PVD, thereby alleviating the vitreomacular traction. The potential use of microplasmin to treat vitreomacular traction could therefore provide a more convenient, much less invasive approach, to both patients and physicians, for the treatment of important back of the eye diseases such as macular holes, diabetic macular edema, diabetic retinopathy in general, and even in age related macular degeneration (AMD), which are caused or exacerbated by the vitreous adhering to the retina abnormally. '/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Kinaxis ®, provider of RapidResponse ®, a cloud-based supply ... ( S&OP ) service, is proud to be a gold ... held at the Hilton San Diego Bayfront, January 30 – ... Kaszas , Director of Supply Chain at Amgen, as she ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... company update at the Deutsche Bank 34th Annual Health Care ... p.m. ET. Interested parties may access a live audio ... the BioMarin website, www.BMRN.com . A ...
... platform for treatment of Spinal Muscular Atrophy SOUTH PLAINFIELD, ... Inc. (PTC) and the Spinal Muscular Atrophy (SMA) Foundation ... which the SMA Foundation will provide up to $8.5 ... second continuation of the collaboration to fund a series ...
... AND STRENGTHENS ITS SENIOR MANAGEMENT TEAM , ... Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in ... today announced that it has strengthened its European presence ... Summa. As Executive Vice President, Europe & Asia/Pacific based ...
Cached Biology Technology:BioMarin to Present at the Deutsche Bank Health Care Conference 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 3OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 2OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 3
(Date:7/10/2014)... and teens living with a cardiac pacemaker, a low ... of life, reports a study in the July ... the official journal of the Society for Developmental ... by Lippincott Williams & Wilkins , a part ... function as a protective factor against lower health-related quality ...
(Date:7/10/2014)... image was collected by the Moderate Resolution Imaging Spectroradiometer ... Each hot spot, which appears as a red mark, ... MODIS instrument recognized temperatures higher than background. When accompanied ... hot spots are diagnostic for fire. , This ... coming directly from the fires, although the smoke released ...
(Date:7/10/2014)... some patients, the chronic inflammatory skin diseases psoriasis* and ... have therefore had to base their decision on which ... an examination of tissue samples. A team of researchers ... of Munich (TUM) have now analyzed the molecular processes ... This has enabled them for the first time to ...
Breaking Biology News(10 mins):For children with pacemakers, 'self-competence' affects quality of life 2New diagnostic test to distinguish psoriasis from eczema 2
... Science-based identification of mold and other causes of ... plant pathologists with The American Phytopathological Society (APS). ... situation in which building occupants experience health problems ... typically associated with SBS range from allergy attacks ...
... South Korean team announced last week that it had ... that were genetically matched to specific people. But their ... Yuri Verlinsky of the Reproductive Genetics Institute, based in ... without resorting to therapeutic cloning. "It would be a ...
... When genes are deleted on a particular section of ... the childhood cancer neuroblastoma. A new study suggests that ... children with neuroblastoma may indicate to physicians that they ... fight the cancer. , Edward F. Attiyeh, M.D., a ...
Cached Biology News:What's really making you sick? Plant pathologists offer the science behind Sick Building Syndrome 2Double triumph in stem cell quest 2Double triumph in stem cell quest 3Double triumph in stem cell quest 4Chromosome Deletion Predicts Aggressive Neuroblastoma 2
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
... Post-Labeling Reactive Dye Pack, 12 x ... specifically optimized for microarray labeling.Higher reactivity ... reactive dye per vial, at > ... individually dispensed, and packed in foil ...
... CyScribe GFX Purification Kit, 24 reactions. ... Cy3- and Cy5-labeled cDNA.Optimized reagents are ... and purification.Flexible and optimized protocols can ... with either Cy3- or Cy5-labeled nucleotides.Reliable ...
Biology Products: